eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
bottom of page